The EMPEROR-Preserved study is the first to demonstrate a significant reduction in risk of cardiovascular death or hospitalization for heart failure (HHF) in HFpEF patients treated with SGLT2 inhibitor empagliflozin (EMPA) (13). This evidence concerns the gene SLC5A2 and heart failure.